Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Fareed, J' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 458 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kaiser, B; Hoppensteadt, DA; Fareed, J
      Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    2. Kanabrocki, EL; George, M; Hermida, RC; Messmore, HL; Ryan, MD; Ayala, DE; Hoppensteadt, DA; Fareed, J; Bremner, FW; Third, JLHC; Shirazi, P; Nemchausky, BA
      Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    3. Cella, G; Sbarai, A; Mazzaro, G; Vanzo, B; Romano, S; Hoppensteadt, D; Fareed, J
      Plasma markers of endothelial dysfunction in chronic obstructive pulmonarydisease

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    4. Stief, TW; Jeske, WP; Walenga, J; Schultz, C; Kretschmer, V; Fareed, J
      Singlet oxygen inhibits agonist-induced P-selectin expression and formation of platelet aggregates

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    5. Cella, G; Sbarai, A; Mazzaro, G; Motta, G; Carraro, P; Andreozzi, GM; Hoppensteadt, DA; Fareed, J
      Tissue factor pathway inhibitor release induced by defibrotide and heparins

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    6. Demir, M; Iqbal, O; Hoppensteadt, DA; Piccolo, P; Ahmad, S; Schultz, CL; Linhardt, RJ; Fareed, J
      Anticoagulant and antiprotease profiles of a novel natural heparinomimeticmannopentaose phosphate sulfate (PI-88)

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    7. Piccolo, P; Iqbal, O; Demir, M; Ma, Q; Gerbutavicius, R; Fareed, J
      Global anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixture

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    8. Santillan, MKO; Herring, J; Hoppensteadt, DA; Jeske, W; Herbert, JM; Fareed, J
      The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    9. Demir, M; Iqbal, O; Untch, B; Hoppensteadt, DA; Gaikwad, BS; Fareed, J
      Ecarin clotting time is sensitive to heparinoids: Comparison of two different techniques

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    10. Demir, M; Iqbal, O; Dietrich, CP; Hoppensteadt, DA; Ahmad, S; Daud, AN; Fareed, J
      Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    11. Daud, AN; Ahsan, A; Iqbal, O; Walenga, JM; Silver, PJ; Ahmad, S; Fareed, J
      Synthetic heparin pentasaccharide depolymerization by heparinase I: Molecular and biological implications

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    12. Hakki, SI; Fareed, J; Hoppensteadt, DA; Abdullah, H; Camblin, J; Nasseri, AF; Hamadeh, O; Wright, T
      Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery (vol 6, pg 206, 2000)

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    13. Nicolaides, AN; Breddin, HK; Fareed, J; Goldhaber, S; Haas, S; Hull, R; Kalodiki, E; Myers, K; Samama, M; Sasahara, A
      Prevention of venous thromboembolism - International Consensus Statement -Guidelines compiled in accordance with the scientific evidence

      INTERNATIONAL ANGIOLOGY
    14. Van Thiel, DH; George, M; Fareed, J
      Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease

      THROMBOSIS AND HAEMOSTASIS
    15. Kaiser, P; Harenberg, J; Walenga, JM; Huhle, G; Giese, C; Prechel, M; Hoppensteadt, D; Fareed, J
      Effects of a heparin-binding protein on blood coagulation and platelet function

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    16. Hoppensteadt, DA; Fareed, J; Raake, P; Raake, W
      Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates

      THROMBOSIS RESEARCH
    17. Pinhal, MAS; Trindade, ES; Fareed, J; Dietrich, CP; Nader, HB
      Heparin and a cyclic octaphenol-octasulfonic acid (GL-522-Y-1) bind with high affinity to a 47-kDa protein from vascular endothelial cell surface andstimulate the synthesis and structural changes of heparan sulfate proteoglycan

      THROMBOSIS RESEARCH
    18. Ahmad, S; Jeske, WP; Ma, Q; Walenga, JM; Fareed, J
      Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist

      THROMBOSIS RESEARCH
    19. Fareed, J; Shaikh, T; Hoppensteadt, DA
      Antithrombin and anti-Xa agents in the control of thrombogenesis

      PHARMAZIE
    20. Cella, G; Bellotto, F; Tona, F; Sbarai, A; Mazzaro, G; Motta, G; Fareed, J
      Plasma markers of endothelial dysfunction in pulmonary hypertension

      CHEST
    21. Lewis, BE; Wallis, DE; Berkowitz, SD; Matthai, WH; Fareed, J; Walenga, JM; Bartholomew, J; Sham, R; Lerner, RG; Zeigler, ZR; Rustagi, PK; Jang, IK; Rifkin, SD; Moran, J; Hursting, MJ; Kelton, JG
      Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia

      CIRCULATION
    22. Fareed, J; Hoppensteadt, DA; Bacher, P; Messmore, HL
      Antithrombin agents: The new class of antithrombotic drugs

      EVIDENCE-BASED MANAGEMENT OF THE ACUTE CORONARY SYNDROME
    23. Iqbal, O; Demir, AM; Hoppensteadt, DA; Wehrmacher, WH; Messmore, HL; Fareed, J
      Thrombolytic therapy in acute coronary syndrome

      EVIDENCE-BASED MANAGEMENT OF THE ACUTE CORONARY SYNDROME
    24. Gerbutavicius, R; Iqbal, O; Messmore, H; Hoppensteadt, DA; Demir, M; Khan, E; Bacher, P; Fareed, J
      Differential effects of unfractionated heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    25. Hakki, SI; Fareed, J; Hoppensteadt, DA; Abdullah, H; Camblin, J; Nasseri, AF; Hamadeh, O; Wright, T
      Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    26. Ahsan, A; Jeske, W; Wolf, H; Fareed, J
      Isoamyl nitrite depolymerized heparin as a universal calibrator for heparins and low molecular weight heparins

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    27. Amin, HM; Ahmad, S; Walenga, JM; Hoppensteadt, DA; Leitz, H; Fareed, J
      Soluble P-selectin in human plasma: Effect of anticoagulant matrix and itslevels in patients with cardiovascular disorders

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    28. Iqbal, O; Messmore, H; Hoppensteadt, D; Fareed, J; Wehrmacher, T
      State-of-the-art review - Thrombolytic drugs in acute myocardial infarction

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    29. Stief, TW; Fareed, J
      The antithrombotic factor singlet Oxygen/Light (O-1(2)/h nu)

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    30. Ahmad, S; Yang, LH; Ahsan, A; Fu, K; Iqbal, O; Hoppensteadt, DA; Lewis, BE; Walenga, JM; Fareed, J
      Pharmacokinetics of argatroban in primates: Evidence on endogenous uptake

      INTERNATIONAL ANGIOLOGY
    31. Kanabrocki, EL; Third, JLHC; Ryan, MD; Nemchausky, BA; Shirazi, P; Scheving, LE; McCormick, JB; Hermida, RC; Bremner, WF; Hoppensteadt, DA; Fareed, J; Olwin, JH
      Circadian relationship of serum uric acid and nitric oxide

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    32. Izban, KF; Lietz, HW; Hoppensteadt, DA; Jeske, WP; Fareed, J; Bakhos, M; Walenga, JM
      Letter to the editor - The authors' response

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    33. Fareed, J; Hoppensteadt, DA; Bick, RL
      An update on heparins at the beginning of the new millennium

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    34. Fareed, J; Hoppensteadt, DA
      Heparins in the new millennium: Will unfractionated heparin survive? Epilogue

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    35. Stief, TW; Kropf, J; Kretschmer, V; Doss, MO; Fareed, J
      Singlet oxygen (O-1(2)) inactivates plasmatic free and complexed alpha(2)-macroglobulin

      THROMBOSIS RESEARCH
    36. Kaiser, B; Paintz, M; Scholz, O; Kunitada, S; Fareed, J
      A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats

      THROMBOSIS RESEARCH
    37. Stief, TW; Kurz, J; Doss, MO; Fareed, J
      Singlet oxygen inactivates fibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood

      THROMBOSIS RESEARCH
    38. Scazziota, A; Altman, R; Rouvier, J; Gonzalez, C; Ahmed, Z; Jeske, WP; Walenga, JM; Fareed, J
      Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression

      THROMBOSIS RESEARCH
    39. Yu, GL; LeBrun, L; Gunay, NS; Hoppensteadt, D; Walenga, JM; Fareed, J; Linhardt, RJ
      Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site

      THROMBOSIS RESEARCH
    40. Ahmad, S; Jeske, WP; Walenga, JM; Aldabbagh, A; Iqbal, O; Fareed, J
      Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: Towards the development of a HIT model in primates

      THROMBOSIS RESEARCH
    41. Matzdorff, AC; Kuhnel, G; Kemkes-Matthes, B; Pralle, H; Voss, R; Fareed, J
      Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro

      JOURNAL OF LABORATORY AND CLINICAL MEDICINE
    42. Fabris, F; Ahmad, S; Cella, G; Jeske, WP; Walenga, JM; Fareed, J
      Pathophysiology of heparin-induced thrombocytopenia clinical and diagnostic implications - A review

      ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
    43. Jeske, W; Hoppensteadt, DA; Pifarre, R; Walenga, JM; Fareed, J
      Mechanism of blood coagulation. Newer aspects of anticoagulant and antithrombotic therapy

      ACUTE PULMONARY EMBOLISM
    44. Ahmad, S; Ahsan, A; George, M; Iqbal, O; Jeske, WP; McKenna, R; Lewis, BE; Walenga, JM; Fareed, J
      Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    45. Ahmad, S; Jeske, WP; Walenga, JM; Hoppensteadt, DA; Wood, JJ; Herbert, JM; Messmore, HL; Fareed, J
      Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    46. Fareed, J; Hoppensteadt, DA; Leya, F; Lewis, B; Callas, D; Wolf, H; Bick, RL
      Thrombogenesis in myocardial infarction and related syndromes: The role ofmolecular markers in diagnosis and management

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    47. Haas, S; Walenga, JM; Jeske, WP; Fareed, J
      Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    48. Ahmad, S; Walenga, JM; Jeske, WP; Cella, G; Fareed, J
      Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    49. Fareed, J; Walenga, JM; Hoppensteadt, DA; Jeske, WP; Ahmad, S; Lietz, H; McKenna, R; Messmore, HL; Haas, S
      Soluble adhesion molecules in the HIT syndrome: Pathophysiologic role and therapeutic modulation

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    50. Fareed, J; Lewis, BE; Callas, DD; Hoppensteadt, DA; Walenga, JM; Bick, RL
      Antithrombin agents: The new class of anticoagulant and antithrombotic drugs

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    51. Bick, RL; Fareed, J
      Low molecular weight heparins: Differences and similarities in approved preparations in the United States

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    52. Kaiser, B; Jeske, W; Walenga, JM; Fareed, J
      Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood

      BLOOD COAGULATION & FIBRINOLYSIS
    53. Ahmad, S; Iqbal, O; Ahsan, A; Hoppensteadt, DA; Lewis, BE; Walenga, JM; Fareed, J
      Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using High Performance Liquid Chromatography and functional methods

      INTERNATIONAL ANGIOLOGY
    54. Dietrich, CP; Paiva, JF; Castro, RAB; Chavante, SF; Jeske, W; Fareed, J; Gorin, PAJ; Mendes, A; Nader, HB
      Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis

      BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
    55. Fareed, J; Hoppensteadt, DA; Jeske, WP; Ahmad, S; Bick, RL
      Acquired defects of fibrinolysis associated with thrombosis

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    56. Fareed, J; Messmore, HL
      Clopidogrel, a new ADP-receptor antagonist: Clinical development - Preface

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    57. Fareed, J
      Epilogue

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    58. Fareed, J; Walenga, JM; Hoppensteadt, DA; Jeske, WP; Lietz, H; Ahmad, S; Callas, D; Messmore, HL; Haas, S
      Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    59. Izban, KF; Lietz, HW; Hoppensteadt, DA; Jeske, WP; Fareed, J; Bakhos, M; Walenga, JM
      Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis ofheparin-induced thrombocytopenia

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    60. Haas, S; Walenga, JM; Jeske, WP; Fareed, J
      Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    61. Walenga, JM; Jeske, WP; Wallis, DE; Bakhos, M; Lewis, BE; Leya, F; Fareed, J
      Clinical experience with combined treatment of thrombin inhibitors and GPIIb IIIa inhibitors in patients with HIT

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    62. Hoppensteadt, DA; Jeske, WP; Walenga, JM; Fu, KD; Yang, LH; Ing, TS; Herbert, JM; Fareed, J
      Laboratory monitoring of pentasaccharide in a dog model of hemodialysis

      THROMBOSIS RESEARCH
    63. Labropoulos, N; Stanley, SK; Kang, SS; Mansour, AM; Fareed, J; Littooy, FN; Baker, WH
      The effects of intermittent pneumatic compression on systemic and local fibrinolysis

      VASCULAR SURGERY
    64. Fareed, J; Callas, D; Hoppensteadt, DA; Lewis, BE; Bick, RL; Walenga, JM
      Antithrombin agents as anticoagulants and antithrombotics: Implications indrug development

      SEMINARS IN HEMATOLOGY
    65. Rabah, MM; Premmereur, J; Graham, M; Fareed, J; Hoppensteadt, DA; Grines, LL; Grines, CL
      Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris

      AMERICAN JOURNAL OF CARDIOLOGY
    66. DRIES DJ; WALENGA JM; HOPPENSTEADT D; FAREED J
      MOLECULAR MARKERS OF HEMOSTATIC ACTIVATION AND INFLAMMATION FOLLOWINGMAJOR INJURY - EFFECT OF THERAPY WITH IFN-GAMMA

      Journal of interferon & cytokine research
    67. FAREED J
      ANTITHROMBIN AGENTS AS ANTICOAGULANTS AND ANTITHROMBOTICS - IMPLICATIONS IN DRUG DEVELOPMENT

      Clinical and applied thrombosis/hemostasis
    68. AHMAD S; AHSAN A; IQBAL O; HOPPENSTEADT DA; LEWIS BE; WALENGA JM; FAREED J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF ARGATROBAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULAR PATIENTS

      Clinical and applied thrombosis/hemostasis
    69. KLAUSER RJ; HOPPENSTEADT D; FAREED J
      TISSUE FACTOR PATHWAY INHIBITOR IS A POTENT INHIBITOR OF PLASMIN

      Clinical and applied thrombosis/hemostasis
    70. DARIEN BJ; FAREED J; CENTGRAF KS; HART AP; MACWILLIAMS PS; CLAYTON MK; WOLF H; KRUSEELLIOTT KT
      LOW-MOLECULAR-WEIGHT HEPARIN PREVENTS THE PULMONARY HEMODYNAMIC AND PATHOMORPHOLOGIC EFFECTS OF ENDOTOXIN IN A PORCINE ACUTE LUNG INJURY MODEL

      Shock
    71. KAISER B; GLUSA E; HOPPENSTEADT DA; BREDDIN HK; AMIRAL J; FAREED J
      A SUPERSULFATED LOW-MOLECULAR-WEIGHT HEPARIN (IK-SSH) INCREASES PLASMA-LEVELS OF FREE AND TOTAL TISSUE FACTOR PATHWAY INHIBITOR AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION IN HUMANS

      Blood coagulation & fibrinolysis
    72. SCHNEIDER DM; VONTEMPELHOFF GF; HOPPENSTAEDT D; FAREED J; HEILMANN L
      ACQUIRED APC-RESISTANCE IN PREGNANT PATIENTS

      Zeitschrift fur Geburtshilfe und Perinatologie
    73. FAREED J; HOPPENSTEADT D; JESKE W; AMIRAL J; WALENGA J
      NONHEPARIN GLYCOSAMINOGLYCANS INDUCED GENERATION OF ANTIPLATELET FACTOR-4 HEPARIN ANTIBODIES - IMPLICATIONS IN THE MANAGEMENT OF HIT SYNDROME

      The FASEB journal
    74. BOZOVICH G; GURFINKEL E; MAUTNER B; BLANCO P; AMIRAL J; FAREED J
      FREE TISSUE FACTOR PATHWAY INHIBITOR IS ELEVATED IN PATIENTS WITH ACUTE NON-Q-WAVE CORONARY SYNDROMES

      The FASEB journal
    75. IQBAL O; CALATZIS A; HAAS S; FAREED J
      COMPARATIVE NEUTRALIZATION OF LOW-MOLECULAR-WEIGHT HEPARINS (LMWH) WITH PROTAMINE AND NEUTRALASE(R)

      The FASEB journal
    76. YANG L; FU K; ARANHA R; FAREED J
      PHARMACOKINETIC AND PHARMACODYNAMICS OF THE ANTIPLATELET ACTIONS OF ASYNTHETIC GPIIB IIIA INHIBITOR, SR121566/

      The FASEB journal
    77. LEITZ H; HOPPENSTEADT D; GEORGE M; FAREED J
      EFFECT OF INTRAVENOUS DEFIBROTIDE TREATMENT ON SOLUBLE P-SELECTIN LEVELS

      The FASEB journal
    78. ASHAN A; IQBAL O; AHMAD S; ANGELATS RS; WALENGA JM; FAREED J
      COMPARATIVE ANALYSES OF CIRCULATING ARGATROBAN LEVELS IN HIT PATIENTSUTILIZING HPLC AND ECT METHODS

      The FASEB journal
    79. GHANI S; FAREED J
      EFFECT OF FACTOR XA INHIBITORS ON THE INTERNATIONAL NORMALIZED RATIO (INR) - LABORATORY AND CLINICAL IMPLICATIONS

      The FASEB journal
    80. HOPPENSTEADT D; FAREED J; AMIRAL J; JESKE W; WALENGA J; LEWIS B; WELZEL D
      TISSUE FACTOR PATHWAY INHIBITOR RELEASE IS SPECIFIC FOR HEPARINS - IMPLICATIONS IN THE MANAGEMENT OF CARDIOVASCULAR SYNDROMES

      The FASEB journal
    81. GEORGE M; HOPPENSTEADT DA; LIETZ H; AHMAD S; FAREED J
      PERFORMANCE-CHARACTERISTICS OF 2 ELISA-BASED METHODS FOR THE QUANTITATION OF SOLUBLE THROMBOMODULIN IN PLASMA

      The FASEB journal
    82. AMIN HM; LIETZ H; HOPPENSTEADT DA; WALENGA JM; GEORGE M; AHMAD S; FAREED J
      QUANTITATION OF SOLUBLE P-SELECTIN IN HUMAN PLASMA - EFFECT OF ANTICOAGULANT MATRIX AND PRELIMINARY CLINICAL-DATA

      The FASEB journal
    83. FAREED D; FAREED J; YANG L; HOPPENSTEADT D; JESKE W; HAAS S; MESSMORE H
      HIRUDIN DOES NOT PREVENT PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIC SYNDROMES

      The FASEB journal
    84. AHMAD S; AHSAN A; IQBAL O; HOPPENSTEADT DA; LEWIS BE; WALENGA JM; FAREED J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF A SYNTHETIC ANTITHROMBIN AGENT, ARGATROBAN, IN MAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULARPATIENTS

      The FASEB journal
    85. FAREED D; FAREED J; YANG L; HOPPENSTEADT D; JESKE W; HAAS S; MESSMORE H
      HIRUDIN DOES NOT PREVENT PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIC SYNDROMES

      Journal of the American College of Cardiology
    86. HOPPENSTEADT D; FAREED J; AMIRAL J; JESKE W; WALENGA JM; LEWIS B; WELZEL D
      TISSUE FACTOR PATHWAY INHIBITOR RELEASE IS SPECIFIC FOR HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARINS - IMPLICATIONS IN THE MANAGEMENT OF CORONARY SYNDROMES

      Journal of the American College of Cardiology
    87. YANG LH; HOPPENSTEADT D; FAREED J
      MODULATION OF VASOCONSTRICTION BY CLOPIDOGREL AND TICLOPIDINE

      Thrombosis research
    88. COYNE E; MESSMORE HL; WALENGA JM; FAREED J; WEHRMACHER WH
      ETHYLENEDIAMINETETRAACETIC ACID (EDTA) IN HEPARIN

      Thrombosis research
    89. FU KD; IZQUIERDO R; VANDEVENDER D; WARPEHA RL; FAREED J
      TRANSPLANTATION OF LYMPH-NODE FRAGMENTS IN A RABBIT EAR LYMPHEDEMA MODEL - A NEW METHOD FOR RESTORING THE LYMPHATIC PATHWAY

      Plastic and reconstructive surgery
    90. KAISER B; HOPPENSTEAD DH; WALENGA JM; GLUSA E; FAREED J
      TISSUE FACTOR PATHWAY INHIBITOR (TFPI) HAS STRONG ANTICOAGULANT AND ANTITHROMBOTIC ACTIONS IN-VITRO AND IN-VIVO

      Naunyn-Schmiedeberg's archives of pharmacology
    91. KAISER B; WALENGA JM; GLUSA E; FAREED J
      THROMBIN GENERATION IN WHOLE-BLOOD IS EFFECTIVELY INHIBITED BY FACTORXA BUT NOT BY THROMBIN INHIBITORS

      Naunyn-Schmiedeberg's archives of pharmacology
    92. KAISER B; GLUSA E; WALENGA JM; FAREED J
      ANTITHROMBOTIC EFFECTS OF FACTOR XA AND THROMBIN INHIBITORS IN A MODEL OF ENDOVASCULAR INJURY IN RABBITS

      Naunyn-Schmiedeberg's archives of pharmacology
    93. FAREED J; CALLAS D; HOPPENSTEADT DA; WALENGA JM; BICK RL
      ANTITHROMBIN AGENTS AS ANTICOAGULANTS AND ANTITHROMBOTICS - IMPLICATIONS IN DRUG DEVELOPMENT

      The Medical clinics of North America
    94. STEVENS RJG; LINTOTT P; HAFEZ H; HOPPENTEADT DA; FAREED J; MANSFIELD AO; NICOLAIDES AN; STANSBY G
      SUPRACOELIAC AORTIC CROSS-CLAMPING CAUSES SYSTEMIC ACTIVATION OF FIBRINOLYSIS IN HUMANS

      Journal of physiology
    95. FAREED J; HOPPENSTEADT DA; LEYA F; IQBAL O; WOLF H; BICK R
      USEFUL LABORATORY TESTS FOR STUDYING THROMBOGENESIS IN ACUTE CARDIAC SYNDROMES

      Clinical chemistry
    96. FAREED J; HOPPENSTEADT DA; JESKE W; AMIRAL J; WALENGA JM
      NON-HEPARIN GLYCOSAMINOGLYCANS-INDUCED GENERATION OF ANTIPLATELET FACTOR-4 HEPARIN ANTIBODIES - IMPLICATIONS IN THE MANAGEMENT OF HIT SYNDROME

      Clinical chemistry
    97. AHMAD S; ASHAN A; WALENGA JM; FAREED J
      DEVELOPMENT OF AN IMPROVED HPLC METHOD FOR THE QUANTITATION OF ARGATROBAN - APPLICATIONS IN THE STUDY OF PHARMACOKINETICS IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY AND THERAPEUTIC ANTICOAGULATION

      Clinical chemistry
    98. IQBAL O; AHMAD S; HOPPENSTEADT DA; LEWIS BE; FAREED J
      SPECIFIC QUANTITATION OF THROMBIN INHIBITORS USING ECARIN CLOTTING TIME - APPLICATION IN POINT OF CARE TESTING

      Clinical chemistry
    99. LEITZ H; HOPPENSTEADT D; BLAKEMORE C; FAREED J
      LABORATORY EVALUATION OF THE MCA-310 FOR COAGULATION-TESTING

      Clinical chemistry
    100. AMIN HM; LIETZ H; HOPPENSTEADT DA; WALENGA JM; GEORGE M; AHMAD S; FAREED J
      IMMUNOQUANTITATION OF SOLUBLE P-SELECTIN IN HUMAN PLASMA - EFFECT OF ANTICOAGULANT MATRIX AND PRELIMINARY CLINICAL-DATA

      Clinical chemistry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/08/20 alle ore 14:49:48